ES2137516T3 - Composicion a base de ciclosporina y su procedimiento de fabricacion. - Google Patents

Composicion a base de ciclosporina y su procedimiento de fabricacion.

Info

Publication number
ES2137516T3
ES2137516T3 ES95920275T ES95920275T ES2137516T3 ES 2137516 T3 ES2137516 T3 ES 2137516T3 ES 95920275 T ES95920275 T ES 95920275T ES 95920275 T ES95920275 T ES 95920275T ES 2137516 T3 ES2137516 T3 ES 2137516T3
Authority
ES
Spain
Prior art keywords
pct
cyclosporine
manufacturing procedure
composition based
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95920275T
Other languages
English (en)
Inventor
Hyun Soo Kim
Jae Yoon Choi
Hye Weon Lee
Young Keun Park
Sung Wook Choi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Application granted granted Critical
Publication of ES2137516T3 publication Critical patent/ES2137516T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

SE REIVINDICA UN COMPUESTO QUE CONTIENE DE UN 1.0% A UN 40% EN PESO DE CICLOSPORINA A, DE UN 0.1% A UN 30% EN PESO DE UN EMULSIONANTE Y DE UN 5% A UN 8O% EN PESO DE UNA DEXTRINA POROSA, SOBRE LA BASE DEL PESO TOTAL DEL COMPUESTO.
ES95920275T 1994-06-01 1995-05-19 Composicion a base de ciclosporina y su procedimiento de fabricacion. Expired - Lifetime ES2137516T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19940012288 1994-06-01
PCT/KR1995/000059 WO1995032726A1 (en) 1994-06-01 1995-05-19 Cyclosporin containing composition and process for the preparation thereof

Publications (1)

Publication Number Publication Date
ES2137516T3 true ES2137516T3 (es) 1999-12-16

Family

ID=19384450

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95920275T Expired - Lifetime ES2137516T3 (es) 1994-06-01 1995-05-19 Composicion a base de ciclosporina y su procedimiento de fabricacion.

Country Status (13)

Country Link
US (1) US5739105A (es)
EP (1) EP0756489B1 (es)
JP (1) JP2936209B2 (es)
KR (1) KR0163212B1 (es)
CN (1) CN1148224C (es)
AT (1) ATE183398T1 (es)
AU (1) AU2577295A (es)
DE (1) DE69511539T2 (es)
DK (1) DK0756489T3 (es)
ES (1) ES2137516T3 (es)
GR (1) GR3031568T3 (es)
RU (1) RU2119351C1 (es)
WO (1) WO1995032726A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618952D0 (en) * 1996-09-11 1996-10-23 Sandoz Ltd Process
KR100241652B1 (ko) * 1997-07-07 2000-03-02 김충섭 이푸리플라본의 경구 투여용 제제의 제조 방법
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US7026290B1 (en) 1998-12-30 2006-04-11 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosprin
EP1058539A1 (en) * 1999-01-06 2000-12-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DK1142566T3 (da) * 2000-04-07 2004-02-09 Medidom Lab Oftalmologiske formuleringer på basis af ciclosporin, hyaluronsyre og polysorbat
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
AR036852A1 (es) * 2001-10-19 2004-10-06 Isotechnika Inc Preconcentrado de una microemulsion de analogos de ciclosporina, su metodo de preparacion y metodos para producir inmunosupresion
US6979672B2 (en) * 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
ATE412400T1 (de) * 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
US7151085B2 (en) 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
EP1843724B1 (en) 2005-02-02 2018-07-25 Össur hf Sensing systems and methods for monitoring gait dynamics
GB0921528D0 (en) 2009-12-09 2010-01-27 Mast Carbon Internat Ltd Carbon and its use in blood cleansing applications
JP6200698B2 (ja) * 2013-06-18 2017-09-20 ニュートリー株式会社 嚥下造影検査食
EP4241760A1 (en) * 2020-11-09 2023-09-13 Scai Therapeutics Co., Ltd. Solid material and dispersion composition containing same
WO2022098122A1 (ko) * 2020-11-09 2022-05-12 주식회사 스카이테라퓨틱스 고상의 사이클로스포린 a 및 이를 포함하는 분산 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8807505D0 (en) * 1988-03-29 1988-05-05 Glaxo Group Ltd Pharmaceutical combinations

Also Published As

Publication number Publication date
ATE183398T1 (de) 1999-09-15
RU2119351C1 (ru) 1998-09-27
KR960000247A (ko) 1996-01-25
EP0756489B1 (en) 1999-08-18
CN1148224C (zh) 2004-05-05
GR3031568T3 (en) 2000-01-31
WO1995032726A1 (en) 1995-12-07
EP0756489A1 (en) 1997-02-05
JP2936209B2 (ja) 1999-08-23
CN1149834A (zh) 1997-05-14
DK0756489T3 (da) 1999-12-06
US5739105A (en) 1998-04-14
AU2577295A (en) 1995-12-21
KR0163212B1 (ko) 1998-12-01
JPH09510733A (ja) 1997-10-28
DE69511539T2 (de) 2000-03-30
DE69511539D1 (de) 1999-09-23

Similar Documents

Publication Publication Date Title
ES2137516T3 (es) Composicion a base de ciclosporina y su procedimiento de fabricacion.
RS49611B (sr) Ziprasidon formulacije
WO2001045647A3 (de) Tablettierung verdickender systeme
BG106030A (en) Pharmaceutical composition
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
SE9604793D0 (sv) New polymorphs
DK0775018T4 (da) Fremgangsmåde til fremstilling af katalysatorer af cobalt på aluminiumoxid
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
ATE204297T1 (de) Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
BG103714A (en) Pararacetamol-containing tablet
DK1131057T3 (da) Polstrende voksperler til fremstilling af faste, formede genstande
HK1043809A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection.
CA2185541A1 (en) Cytotoxic t-cell epitopes
DE69513157D1 (de) Heterofunktionelle mucoadhäsive galenische zusammensetzung
ZA961364B (en) 1-Aryl-2-acylamino-ethane compounds
WO2001078682A3 (en) Sustained release drug compositions
CA2174707A1 (en) Chromone derivatives as nk1 and substance p antagonists
FR2693746B1 (fr) Compositions a base de cire et contenant des agents tensio-actifs amphoteres, leur preparation et leur utilisation comme agents de finissage.
BR0207066A (pt) Derivados do 2h-1-benzopirano - processos para sua preparação e composições farmacêuticas a partir deles
BR0012751A (pt) Benzofuranos serotonérgicos
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
HRP20000400B1 (en) Transmucosal formulations of levosimendal
ATE251457T1 (de) Substituierte 1,2,3,4-tetrahydro-2- dibenzofuranamine und 2- aminocyclohepta(b)benzofurane

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 756489

Country of ref document: ES